Redeye provides an initial comment on the Q2 2025 report from Catella.
* Sales -4% vs. ABGSCe at SEK 55m * EBITDA better than expected (SEK -0.
* Stable occupancy and positive net letting * Cons to lower estimates (rec.
* Q2 EBIT of SEK 315m, +11% vs. ABGSC and +7% vs. consensus * Announces buyback of bonds of max SEK ...
Redeye comments on Better Collective’s Q2-results which were slightly below our forecast owing mainl...
Redeye provides its initial take on Surgical Science’s Q2 2025 report, which aligned with its profit...
* Q2 in line, with automotive market and FX posing headwinds * Some uncertainty about targets, but v...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with H...
Redeye provides an update following Paxman’s Q2 2025 report.
Investors House's Q2 report was overshadowed by the announcement that the board will propose an extr...
Qbim är ett svenskt bolag verksamt inom business intelligence- och dataanalys.
Redeye clarifies the changes in the fair value range.
Redeye updates its Q2 estimates ahead of Thunderful’s quarterly report on August 27.
Redeye provides a research update following the Q2 report published by Cinclus earlier today.
- Q2 figures in line with pre-announcement - '25e-'27e sales cut by 11% on softer Q2 - Inventory nor...
- Strong growth and gross margin continued in Q2'25 -EBIT revised up by 11% for '25e and 4% for '26e...
Ventilationsbolaget Systemair rapporterar ökad utdelning och vd-byte till Robert Larsson inför årsst...
Redeye returns with a more in-depth take on Q2 earnings.
Redeye provides an initial take on the Q2 2025 report from Cheffelo, which came in slightly below ou...
Redeye provides an initial take following Paxman’s Q2 2025 report.
